Relmada Therapeutics Inc SEC Filings

Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.

Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.